Prescription for Profit: Pharmaceutical-Biotech Industry's 2016 Outlook

Researched by Annette Kreuger, Global VP Pharmaceutical-Biotech Group--With current economic reports going from bad to worse, the Pharmaceutical-Biotech Industry shines a strong ray of economic light. Despite the roller coaster rise and fall of the economic scene, the fact remains that a successful drug that the public either needs or desires, requires the facilities to develop, test, produce, package and distribute it. The epic rate of new drug approvals--paired with an ever expanding client base--is helping to fuel the growth in facilities across the globe.

The total investment value (TIV) for North American projects that were scheduled to begin construction in 2016, but have been canceled or placed on hold, or had their construction kickoff dates moved out to another year, stood at a little more than $118 billion at the end of January. This is a 6.44% improvement from the "fallout" figure a year ago for 2015.

The North American transmission buildout remains alive and well, with more than 400 projects valued at more than $54 billion scheduled to kick off construction in the next five years. Within North America, the U.S. is the leading national market, and within the U.S., no region expects to see more project activity than the Rocky Mountains market, with more than $18 billion of active projects under development.

North America Chemical Processing Industry Potential Spending Activities - 2016 Edition

Industrial Info's North American Chemical Processing Industry Potential Spending Activities Wall Map provides an overview of 2,600+ Chemical Processing Industry projects...